Sanofi

Sanofi defends top oncology drug with Jevtana patent win
Sanofi defends top oncology drug with Jevtana patent win
Fierce Pharma
Sanofi
patents
generics
Jevtana
oncology
Flag link:
Dupixent brings long-awaited profits to Sanofi, Regeneron partnership
Dupixent brings long-awaited profits to Sanofi, Regeneron partnership
BioPharma Dive
Sanofi
Regeneron
Dupixent
Flag link:
Sanofi ends partnership with Lexicon after trial failure
Sanofi ends partnership with Lexicon after trial failure
In-Pharma Technologist
Sanofi
Lexicon Pharmaceuticals
clinical trials
Zynquista
diabetes
Flag link:
New York investigating 3 insulin makers' pricing strategies
New York investigating 3 insulin makers' pricing strategies
Beckers Hospital Review
New York
insulin
diabetes
Sanofi
Eli Lilly
Novo Nordisk
Flag link:
Thrashed by a 'surprise' rival, Sanofi writes off $2B on soured hemophilia deal
Thrashed by a 'surprise' rival, Sanofi writes off $2B on soured hemophilia deal
Endpoints
Sanofi
earnings
Roche
Hemlibra
hemophilia
Eloctate
Flag link:
Sanofi ups revenues forecasts as eczema drug Dupixent surges
Sanofi ups revenues forecasts as eczema drug Dupixent surges
Pharmaforum
Sanofi
earnings
Dupixent
Flag link:
Sanofi's Earnings: A Preview
Sanofi's Earnings: A Preview
Yahoo/Benzinga
Sanofi
earnings
Flag link:
Drugmakers will profit from climate change, Morgan Stanley says
Drugmakers will profit from climate change, Morgan Stanley says
Beckers Hospital Review
climate change
Morgan Stanley
Merck
Sanofi
vaccines
GSK
Takeda
JNJ
Moderna Therapeutics
Flag link:
Sanofi ends partnership with Lexicon to develop add-on pill for diabetes
Sanofi ends partnership with Lexicon to develop add-on pill for diabetes
Yahoo/Reuters
Sanofi
Lexicon Pharmaceuticals
type 1 diabetes
type 2 diabetes
diabetes
insulin
Flag link:
Janssen’s Ponesimod Finds Success in Head-to-Head Multiple Sclerosis Trial
Janssen’s Ponesimod Finds Success in Head-to-Head Multiple Sclerosis Trial
BioSpace
Janssen
JNJ
ponesimod
Sanofi
Aubagio
relapsing multiple sclerosis
Flag link:
Roche cuts loose Tamiflu OTC rights, handing Sanofi the keys as the pharma giant doubles down on Xofluza
Roche cuts loose Tamiflu OTC rights, handing Sanofi the keys as the pharma giant doubles down on Xofluza
Endpoints
Roche
Tamiflu
OTC
Xofluza
Sanofi
Flag link:
MyoKardia cuts all ties to Sanofi
MyoKardia cuts all ties to Sanofi
Biopharma Dive
MyoKardia
MYK-224
Sanofi
obstructive hypertrophic cardiomyopathy
mavacamten
Flag link:
Pharma Stock Roundup: Pipeline & Regulatory Updates by MRK, GSK, SNY
Pharma Stock Roundup: Pipeline & Regulatory Updates by MRK, GSK, SNY
Yahoo/Zacks.com
GSK
HIV
FDA
Merck
Keytruda
Sanofi
isatuximab
Roche
JNJ
Flag link:
German court blocks sale of Sanofi, Regeneron cholesterol drug
German court blocks sale of Sanofi, Regeneron cholesterol drug
Biopharma Dive
patents
Amgen
Sanofi
Regeneron
Germany
Praluent
Repatha
Flag link:
FDA accepts BLA filing for Sanofi's rival to J&J's Darzalex
FDA accepts BLA filing for Sanofi's rival to J&J's Darzalex
Fierce Biotech
Sanofi
FDA
Darzalex
relapsed or refractory multiple myeloma
isatuximab
Flag link:
With FDA spanking, Biocon and Mylan face new hurdle for Lantus challenger
With FDA spanking, Biocon and Mylan face new hurdle for Lantus challenger
Fierce Pharma
FDA
Biocon
Mylan
Sanofi
Lantus
insulin
drug manufacturing
Flag link:
Sanofi and Regeneron's Dupixent scores 3rd FDA approval in sinusitis with nasal polyps
Sanofi and Regeneron's Dupixent scores 3rd FDA approval in sinusitis with nasal polyps
Fierce Pharma
Sanofi
Regeneron
Dupixent
rhinosinusitis
nasal polyps
FDA
Flag link:
Pharma's got its chief digital officers. Now let's see results: Sanofi executive
Pharma's got its chief digital officers. Now let's see results: Sanofi executive
Fierce Pharma
digital pharma
digital medicine
Sanofi
Flag link:
FDA Action Alert: Regeneron, Sanofi, Celgene
FDA Action Alert: Regeneron, Sanofi, Celgene
BioSpace
FDA
drug approvals
Acer Therapeutics
Edsivo
Regeneron
Sanofi
Dupixent
Celgene
Revlimid
Alexion
Soliris
Dova Pharmaceuticals
Doptelet
Nabriva Therapeutics
Contepo
Retrophin
Thiola
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Yahoo/Benzinga
Merck
Keytruda
Melinta Therapeutics
Amag Pharmaceuticals
Palatin
Acer Therapeutics
Sanofi
Regeneron
Alexion
Pfizer
Roche
Navidea Biopharmaceuticals
Ascendis Pharma
Scholar Rock
Adaptive Biotechnologies
BridgeBio
IPOs
G Medical Innovations
Karuna
Morphic Therapeutics
Flag link:

Pages